Piper Jaffray is out with a research report on Meridian Bioscience VIVO and it has an Underweight rating and a $14 price target on shares.
In a note to clients, Piper Jaffray writes, "We are initiating coverage of Meridian Biosciences with an Underweight rating and $14 price target. Meridian recently launched its first molecular diagnostic assay for C. difficile (a bacterial hospital-acquired infection) on its illumigene system, with a building infectious disease pipeline. We believe near-term conversion of Meridian's legacy immunoassay-based C. difficile customers to illumigene will be critical to
meet forward expectations; however given the current (e.g. BDX, CPHD, GPRO) and expected competitors (DHR (BEC), BIM-FP) with broader assay menus and more flexible technologies we see risk to consensus expectations. Additionally, we believe performance will have to improve within 12-18 months to avoid cutting dividend
growth (or the dividend outright)."
Shares of VIVO closed at $17.21 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in